May 23, 2026 | Burma Independent Voice (BIV)
DAVIS, California — Researchers at the University of California, Davis (UC Davis) have engineered a groundbreaking class of non-hallucinogenic psychotropic compounds that effectively combat anxiety and depression in laboratory tests without triggering sensory distortions or “trips.”
While traditional psychedelic-like drugs are known to highly stimulate neuroplasticity—the brain’s ability to grow new neural pathways—their therapeutic viability is often limited by severe hallucinogenic side effects. The newly synthesized compound offers an innovative model for neurotherapeutics, successfully decoupling the antidepressant benefits of psychedelics from their mind-altering properties.
De Novo Chemical Engineering
Historically, efforts to discover safer psychotropic medicines relied heavily on making incremental structural modifications to existing illicit or naturally occurring molecules, such as LSD or psilocybin. The UC Davis research team abandoned this convention, opting instead for a de novo (from the beginning) approach utilizing common dietary amino acids as structural building blocks.
Graduate researcher Joseph Beckett and his colleague Trey Brasher pioneered the method by combining tryptamine—a naturally occurring trace amine in the human body—with specific amino acids under ultraviolet (UV) light irradiation. The photochemical reactions broke down old chemical structures and forged entirely new chemical bonds, generating pristine molecular architectures never before documented in organic chemistry. Researchers noted this UV-driven method is significantly cleaner, faster, and more efficient than traditional drug discovery protocols.
The “D5” Compound and the Head-Twitch Test
From an initial library of $100$ newly synthesized compounds, the team identified five molecules capable of fully activating serotonin receptors in the brain. These five candidates were subsequently advanced to in vivo laboratory testing on mice. Among them, the most potent responder was designated as “D5.”
Under standard pharmacological theory, full activation of specific serotonin receptors linked to hallucinations predictably causes mice to exhibit a distinct “head-twitch response” (HTR). Surprisingly, even when administered in exceptionally high doses, the D5 compound provoked no head-twitch behavior whatsoever. Beyond its lack of hallucinogenic markers, D5 demonstrated the capacity to actively suppress head twitches induced by other psychotropic agents.
“While other research groups are trimming and modifying existing illicit substances, our D5 molecule was built entirely from scratch,” co-author Trey Brasher explained. “It possesses no direct ancestral lineage to known scheduled drugs. This represents a completely new therapeutic paradigm for medical science.”
While the precise cellular mechanism remains under investigation, scientists hypothesize that D5 may concurrently engage secondary receptor pathways that actively mute or override hallucinogenic signaling cascades mid-stream.
Implications for Clinical Psychiatry
If these preclinical findings translate successfully through upcoming animal safety models and human clinical trials, D5 could radically democratize depression treatments.
Because the drug does not cause cognitive disorientation or impairment, patients could safely self-administer the medication at home without the mandatory clinical supervision required for traditional psychedelics. Furthermore, this non-hallucinogenic mechanism opens a safe therapeutic avenue for severe depression patients with a personal or family history of psychosis—a vulnerable demographic previously disqualified from psychedelic-assisted therapies due to the risk of triggering psychotic episodes.
The complete peer-reviewed study and its chemical methodologies have been published in the prestigious Journal of the American Chemical Society.
